ESR1 and breast cancer: Based on the expression of hormonal receptors (estrogen—ER and progesterone—PR) and the human epidermal growth factor receptor 2 (HER2) amplification, BC is classified as luminal (ER and/or PR+), HER2-amplified (any ER/PR status), or triple-negative (ER and PR -).